Main Article Content

Abstract

The literature review presents the results of studies on various aspects of the combination of bronchial asthma and COVID-19. In particular, the issues of the frequency of bronchial asthma among patients with confirmed COVID-19, the influence of bronchial asthma on the risk of developing a new coronavirus infection, the peculiarities of the course of bronchial asthma in patients with COVID-19 are discussed. The features of the use of individual components of basic therapy of bronchial asthma during the pandemic, in particular, inhaled and systemic corticosteroids, antileukotriene medicals, targeted therapy, are considered. Attention is paid to recommendations on the choice of devices for the administration of inhaled medications in the light of prevention of the spread of a new coronavirus infection.

Keywords

bronchial asthma COVID-19 comorbidity

Article Details

How to Cite
Akbarovna , N. M. (2022). Issues of Comorbidity of Bronchial Asthma and Covid-19. Central Asian Journal of Medical and Natural Science, 3(6), 1-11. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1160

References

  1. 1. Гудима Г.О., Хаитов Р.М., КудлайД.А., ХаитовМ.Р. Молекулярно-иммунологические аспекты диагностики, профилактики и лечения коронавирусной инфекции// Иммунология. ‒2021.‒Т.42,№3.‒С.198-210.DOI: https://doi.org/10.33029/0206-4952-2021-42-3-198-210.
  2. 2. Ермолова А.В., Будневский А.В., Малыш Е.Ю., Овсянников Е.С., Дробышева Е.С. Бронхиальная астма и метаболический синдром// Клиническая медицина.–2015.–Т. 93, №6.–С.44-49.
  3. 3. Петров Д.В., Белевский А.С. Ведение пациентов с бронхиальной астмой в условиях пандемии COVID-19// Астма и аллергия.–2020.‒№1.–С.6-11.
  4. 4. Провоторов В. М., Будневский А. В., Филатова Ю. И. Клинические проявления бронхиальной астмы под влиянием комплексной терапии с применением церулоплазмина// Терапевтический архив. – 2016. – Т.88, № 3. – С. 36-39. DOI:10.17116/terarkh201688336-39.
  5. 5. Провоторов В. М., Будневский А. В., Филатова Ю. И., Перфильева М. В. Антиоксидантная терапия при бронхиальной астме // Клиническая медицина.–2015.–Т. 93,№8.–С.19-22.
  6. 6. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2019. https://spulmo.ru/upload/kr_bronhastma_2019.pdf Датаобращения23.03.21.
  7. 7. Фомина Д.С., Сердотецкова С.А., Иванова М.С. и др. Ведение пациентов с COVID-19 и бронхиальной астмой: обзор литературы и клинический опыт авторов//Практическая пульмонология.–2020.–№2.–С.3-15.
  8. 8. Хлудова Л. Г. Бронхиальная астма и COVID-19 // Астма и аллергия. – 2020.‒№1.–С.3-5.
  9. 9. Abrams E. M., Greenhawt M. Risk communication during COVID-19// J. Allergy Clin. Immunol.Pract. – 2020. – Vol. 8, № 6. ‒ Р. 1791-1794. DOI: 10.1016/j.jaip.2020.04.012.
  10. 10. Abrams E.M., Szefler S.J. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents // J.Pediatr.–2020.–Vol.222.–Р.221-226.DOI:10.1016/j.jpeds.2020.04.049.
  11. 11. Amirav I., Newhouse M.T. Transmission of coronavirus by nebulizer: aserious, under appreciated risk // CMAJ. – 2020. – Vol. 192, № 13. – Е346. DOI: 10.1503/cmaj.75066.
  12. 12. ArabiY. M., MandourahY., Al-Hameed F. et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome // Am. J. Respir. Crit. Care Med. – 2018. – Vol. 197, № 6. – Р. 757-767. DOI: 10.1164/rccm.201706-1172OC.
  13. 13. AriA. Promoting saf and effective use of aerosol devices in COVID-19:risks and suggestions for viral transmission. Expert. Opin. Drug. Deliv., 2020, vol.17, no.11, pp.1509-1513.doi:10.1080/17425247.2020.1811225.
  14. 14. Avdeev S., Moiseev S., Brovko M. etal. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy, 2020, vol.75, no.10, pp.2703-2704.doi:10.1111/all.14420.
  15. 15. Bhatraju P. K., Ghassemieh B. J., Nichols M. et al. Covid-19 in critically ill patients in the Seattleregion‒Caseseries. N. Engl.J. Med., 2020, vol.382, no. 21, pp. 2012-2022.doi:10.1056/nejmoa2004500.
  16. 16. Bousquet J., Bergmann K.C., Zuberbier T., Bedbrook A., Onorato G. L., JutelM., Akdis C.A., Akdis M., Klimek L., Pfaar O., Nadeau K.C., Chinthrajah S., Eiwegger T., Ansotegui I. J., Anto J. M., Bachert C., Bateman E. D., Bennoor K. S., Berghea E. C., Blain H.etal. ARIA-EAACI statementon Asthmaand COVID-19 (JUNE2, 2020). Allergy, 2021, vol.76, no.3, pp.689-697. doi:10.1111/all.14471.
  17. 17. Bozek A., WintersteinJ. Montelukast’sability to fight COVID-19infection. J. Asthma, 2020, pp. 1-2. doi:10.1080/02770903.2020.1786112.
  18. 18. Brough H.A., Kalayci O., Sediva A. et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics ‒ The 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics. Pediatr. Allergy Immunol.,2020, vol. 31, no. 5, pp. 442-448.doi:10.1111/pai.13262.
  19. 19. ChenN., ZhouM., DongX. etal. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, vol. 15, no. 395, pp. 507-513. doi: 10.1016/S0140-6736(20)30211-7.
  20. 20. Chhiba K.D., Patel G.B., Vu T.H.T. et al. Prevalence and characterization of asthma in hospitalized and no hospitalized patients with COVID-19. J. Allergy Clin. Immunol.,2020, vol. 146, no. 2, pp. 307-314.e4. doi:10.1016/j. jaci.2020.06.010.
  21. 21. ChongmelaxmeB., LeeS., DhippayomT. etal. The effects of tele medicine on asthma control and patients’quality of life in adults: a systematic review and meta-analysis. J.Allergy Clin.Immunol.Pract., 2019, vol.7, no.1, pp.199-216. e11. doi:10.1016/j.jaip.2018.07.015.
  22. 22. ChowN.,Fleming-DutraK.,GierkeR.etal.Preliminaryestimatesofthe prevalenceofselectedunderlyinghealthconditionsamongpatientswith coronavirusdisease2019‒UnitedStates,February12March28,2020.MMWR MorbMortalWklyRep.,2020,vol.69,no.13,pp.382-386.doi:10.15585/mmwr. mm6913e2.
  23. 23. CrimiC.,ImpellizzeriP.,CampisiR.etal.Practicalconsiderationsforspirometry duringtheCOVID-19outbreak:literaturereviewandinsights.Pulmonology, 2020, S2531-0437(20)30175-6. doi:10.1016/j.pulmoe.2020.07.011.
  24. 24. DempseyO.Leukotrienereceptorantagonisttherapy.PostgradMed.J.,2000, vol.76,no.902,pp.767-773.doi:10.1136/pgmj.76.902.767.
  25. 25. DochertyA.B.,HarrisonE.M.,GreenC.A.etal.Featuresof20133UKpatients inhospitalwithCOVID-19usingtheISARICWHOClinicalCharacterisationProtocol: prospective observational cohort. BMJ, 2020, vol. 369. m1985. doi:10.1136/bmj.m1985.
  26. 26. DongX.,CaoY.Y.,LuX.X.etal.Elevenfacesofcoronavirusdisease2019.Allergy, 2020,vol.75,no.7,pp.1699-1709.doi:10.1111/all.14289.
  27. 27. Drummond M. Sleep labs, lung function tests and COVID-19 pandemic– onlyemergenciesallowed!Pulmonology,2020,vol.26,no.4,pp.244-245.doi: 10.1016/j.pulmoe.2020.04.002.
  28. 28. DuY.,TuL.,ZhuP.etal.Clinicalfeaturesof85fatalcasesofCOVID-19from Wuhan.Aretrospectiveobservationalstudy.Am.J.Respir.Crit.CareMed.,2020, vol.201,no.11,pp.1372-1379.doi:10.1164/rccm.202003-0543OC.
  29. 29. EsquivelA.,BusseW.W.,CalatroniA.etal.Effectsofomalizumabonrhinovirus infections,illnesses,andexacerbationsofasthma.Am.J.Respir.Crit.CareMed., 2017,vol.196,no.8,pp.985-992.doi:10.1164/rccm.201701-0120OC.
  30. 30. FerastraoaruD.,HudesG.,JerschowE.etal.Eosinophiliainasthmapatients isprotectiveagainstsevereCOVID-19illness.J.AllergyClin.Immunol.Pract.,2021,vol.9,no.3,pp.1152-1162.e3.doi:10.1016/j.jaip.2020.12.045.
  31. 31. GargS.,KimL.,WhitakerM.etal.Hospitalizationratesandcharacteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET,14States,March1-30,2020.MMWRMorbMortalWkly Rep.,2020,vol.69,no.15,pp.458-464.doi:10.15585/mmwr.mm6915e3.
  32. 32. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020. https://ginasthma. org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf (Accessed March 23,2021).
  33. 33. GosensR.,GrossN.Themodeofactionofanticholinergicsinasthma//Eur. Respir.J.–2018.–Vol.52,№4.–Р.701247.DOI:10.1183/13993003.01247-2017.
  34. 34. Grandbastien M., Piotin A., Godet J.et al. SARS-CoV-2 pneumonia inhospitalizedasthmaticpatientsdidnotinducesevereexacerbation//
  35. 35. J. Allergy Clin. Immunol.Pract. – 2020. – Vol. 8, № 8. – Р. 2600–2607.DOI: 10.1016/j.jaip.2020.06.032.
  36. 36. GuanW.J.,NiZ.Y.,HuY.etal.Clinicalcharacteristicsofcoronavirusdisease 2019inChina//N.Engl.J.Med.–2020.–Vol.382,№18.–Р.1708-1720.DOI: 10.1056/NEJMoa2002032.
  37. 37. HalpinD. M, Singh D., Hadfield R. M. et.al. Inhaled corticosteroids and COVID-19:asystematicreviewandclinicalperspective//Eur.Respir.Soc.– 2020.–Vol.55,№5.–Р.2001009.DOI:10.1183/13993003.01009-2020.
  38. 38. Interim guidance about COVID-19 and asthma. Updated 20 Dec 2020. https://ginasthma.org/wp-content/uploads/2020/12/GINA-interim-guida nce-on-COVID-19-and-asthma-20_12_20.pdf(AccessedMarch20,2021).
  39. 39. IwabuchiK.,YoshieK.,KurakamiY.et.al.Therapeuticpotentialofciclesonideinahalation for COVID-19 pneumonia: Report of three cases // J. Infect. Chemother.–2020.–Vol.26,№6.–Р.625-632.DOI:10.1016/j.jiac.2020.04.007.
  40. 40. JacksonD.J.,BusseW.W., BacharierL.B.etal.Associationofrespiratory allergy,asthma,andexpressionoftheSARS-CoV-2recepto2rACE2//J.Allergy Clin. Immunol. – 2020. – Vol. 46, № 1. – Р. 203-206.e3. DOI: 10.1016/j. jaci.2020.04.009.
  41. 41. KhanA.,MisdaryC.,Yegya-RamanN.etal.Montelukastinhospitalized patients diagnosed with COVID-19 // Research Square. – 2020. DOI:10.21203/rs.3.rs-52430/v1.
  42. 42. KhanM.,KhanM.N.,MustagirM.G.etal.Effectsofpre-existingmorbidities on occurrence of death among COVID-19 disease patients: a systematic reviewandmeta-analysis//J.Global.Health.–2020.–Vol.10,№2.–020503. DOI:10.7189/jogh.10.020503.
  43. 43. KlimekL.,JutelM.,AkdisC.etal.Handlingofallergenimmunotherapyinthe COVID-19pandemic:anARIA-EAACI statement//Allergy.–2020.–Vol.75,
  44. 44. № 7. – Р. 1546-1554. DOI: 10.1111/all.14336.
  45. 45. KonopkaK.E.,WilsonA.,MyersJ.L.Postmortemlungfindingsinapatient withasthmaandcoronavirusdisease2019//Chest.–2020.–Vol.158,№3.– Р. e99-e101. DOI:10.1016/j.chest.2020.04.032.
  46. 46. KumarK.,HinksT.S.C.,SinganayagamA.TreatmentofCOVID-19-exacerbated asthma: should systemic corticosteroids be used? // Am. J. Physiol. Lung. Cell. Mol. Physiol. – 2020. – Vol. 318, № 6. – Р. L1244-L1247. DOI: 10.1152/ajplung.00144.2020.
  47. 47. Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adult COVID-19inpatientsinWuhan//J.AllergyClin.Immunol.–2020.– Vol. 146,
  48. 48. № 1. – Р. 110-118. DOI: 10.1016/j.jaci.2020.04.006.
  49. 49. LicskaiC.,YangC.L.,DucharmeF.M.etal.Addressingtherapeuticquestions tohelpCanadianphysiciansoptimizeasthmamanagementfortheirpatients duringtheCOVID-19pandemic//Can.J.Respir.Crit.CareSleep.Med.– 2020.–Vol.4,№2.–Р.73-76.DOI:10.1080/24745332.2020.1754027.
  50. 50. LindsleyA.W.,SchwartzJ.T.,RothenbergM.E.Eosinophilresponsesduring COVID-19infectionsandcoronavirusvaccination//J.AllergyClin.Immunol.– 2020.–Vol.146,№1.‒Р.1-7.DOI:10.1016/j.jaci.2020.04.021.
  51. 51. Liu S., ZhiY., Ying S. COVID-19 and asthma: reflection during the pandemic//Clin.Rev.AllergyImmunol.–2020.–Vol.59,№1.–Р.78-88. DOI:10.1007/s12016-020-08797-3.
  52. 52. MatsuyamaS.,KawaseM.,NaoN.etal.Theinhaledcorticosteroidciclesonide blockscoronavirusRNAreplicationbytargetingviralNSP15//BioRxiv.–2020. DOI:10.1101/2020.03.11.987016.
  53. 53. PenningtonE.AsthmaincreasesriskofseverityofCOVID-19//CleveClin.J. Med. ‒ 2020.DOI:10.3949/ccjm.87a.ccc002.
  54. 54. Peters M. C., Sajuthi S., DefordP.et al. COVID-19-related genesin sputum cells in asthma. Relationship to demographic features and corticosteroids // Am. J. Respir. Crit. Care Med. – 2020. – Vol. 202, № 1. – Р. 83-90. DOI:10.1164/rccm.202003-0821OC.
  55. 55. RiggioniC.,ComberiatiP.,GiovanniniM.etal.Acompendiumanswering 150 questions on COVID-19 and SARS-CoV-2 // Allergy. – 2020. –Vol. 75,
  56. 56. № 5.– Р. 2503-2543. DOI: 10.1111/all.14449.
  57. 57. SajuthiS.P.,DeFordP.,JacksonN.D.etal.Type2andinterferoninflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium//Biorxiv.–2020.DOI:10.1038/s41467-020-18781-2.
  58. 58. Schleicher G. K., Lowman W., Richards G. A. Case study: a patient with asthma,Covid-19pneumoniaandcytokinereleasesyndrometreatedwith corticosteroidsandtocilizumab//WitsJ.Clin.Med.–2020.–№2(SI).‒P.47-52.
  59. 59. ShangL.,ZhaoJ.,HuY.et.al.Ontheuseofcorticosteroidsfor2019-nCoV pneumonia. Lancet, 2020, vol. 395, no. 10225, pp. 683-684. doi: 10.1016/S0140-6736(20)30361-5.
  60. 60. Starshinova A., Malkova A., ZinchenkoU., Kudlay D., GlushkovaA., DovgalykI.,YablonskiyP.,ShoenfeldY.Efficacyofdifferenttypesoftherapy forCOVID-19:Acomprehensivereview.Life,2021,no.11,pp.753.https://doi. org/10.3390/life11080753.
  61. 61. Vultaggio A., Agache I., Akdis C.A. et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement. Allergy, 2020, vol. 75, no. 11, pp. 2764-2774. doi: 10.1111/all.14407.
  62. 62. Wan G.-H., Tsai Y.-H., Wu Y.-K., TsaoK.-C. A large-volume nebulizer would notbeaninfectioussourceforsevereacuterespiratorysyndrome.Infect.Control Hosp. Epidemiol., 2004, vol. 25, no. 12, pp. 1113-1115. doi:10.1086/502353.
  63. 63. WangD.,HuB.,HuC.etal.Clinicalcharacteristicsof138hospitalizedpatients with2019novelcoronavirus-infectedpneumoniainWuhan,China.JAMA, 2020,vol.323,no.11,pp.1061-1069.doi:10.1001/jama.2020.1585.
  64. 64. WangY.,Jiang W., HeQ.etal.Early,low-doseandshort-termapplication ofcorticosteroidtreatmentinpatientswithsevereCOVID-19pneumonia: single-centerexperiencefromWuhan,China.medRxiv,2020.doi:10.1101/2 020.03.06.20032342.
  65. 65. YamayaM.,NishimuraH.,DengX.etal.Inhibitoryeffectsofglycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelialcells.Respir.Investig.,2020,vol.58,no.3,pp.155-168.doi:10.1016/j. resinv.2019.12.005.
  66. 66. ZhangJ.J.,CaoY.Y.,DongX.etal.DistinctcharacteristicsofCOVID-19patients withinitialrRT-PCR-positiveandrRT-PCR-negativeresultsforSARS-CoV-2. Allergy,2020,vol.75,no.7,pp.1809-1812.doi:10.1111/all.14316.
  67. 67. Zhang J.J., Dong X., Cao Y.Y. et al. Clinical characteristics of 140 patients infectedwithSARS-CoV-2inWuhan,China.Allergy,2020,vol.75,no.7, pp. 1730-1741.doi:10.1111/all.14238.
  68. 68. ZhangW.,LinC.,SampathV.,NadeauK.Impactofallergenimmunotherapy in allergic asthma. Immunotherapy, 2018, vol. 10, no. 7, pp. 579-593. doi: 10.2217/imt-2017-0138.
  69. 69. Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predispositionwiththeriskofsevereCOVID-19.J.AllergyClin.Immunol.,2020,vol.146,no.2,pp.327-329.e4.doi:10.1016/j.jaci.2020.06.001.
  70. 70. НигматуллаеваМ. А.,ТиллоеваШ. Ш. СвязьМетаболическогоСиндромаСРазличнымиНарушениямиРитмаСердца //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2021. – Т. 1. – №. 1. – С. 40-49.
  71. 71. M. A. , N. (2022). Positive Trend of Treatment With Equator and Tessiron in Patients With Nonspecific Aorto-Arteritis. Central Asian Journal of Medical and Natural Science, 3(5), 404-407. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1112
  72. 72. Nigmatullayeva M. A. et al. Covid-19 and Bronchial Asthma (Clinical and Epidemiological Aspects) //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2022. – Т. 3. – №. 3. – С. 353-361.
  73. 73. Nigmatullaeva M. A. et al. RELATIONSHIP OF METABOLIC SYNDROME WITH DIFFERENT HEART RATE DISORDERS //Web of Scientist: International Scientific Research Journal. – 2021. – Т. 2. – №. 12. – С. 547-556.
  74. 74. Рахимова Г. Ш. ИНТЕРПРЕТАЦИЯ МАКРОСКОПИЧЕСКОЙ ТОПОГРАФИИ СЕМЕННИКОВ ПОДОПЫТНЫХ БЕЛЫХ КРЫС ПОСЛЕ МОДЕЛИРОВАННОЙ ЧЕРЕПНО-МОЗГОВОЙ ТРАВМЫ //ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ. – С. 83.
  75. 75. Shamsievna R. G. Modern Aspects of Studying the Features of Morphofunctional Characteristics of Testes under Various Factor Influences //Eurasian Scientific Herald. – 2022. – Т. 7. – С. 279-286
  76. 76. Rakhimova G. Sh. «Experimental modelling of traumatic brain injury in white rats».Тиббиётда янги кун. –2021, 2/34 С-197-200
  77. 77. Рахимова Г. Ш. Тажрибадаги оғир бош мия шикастланишидан кейин 3 ойлик оқ каламуш уруғдонларининг макроскопик хусусиятлари //Barqarorlik va yetakchi tadqiqotlar onlayn ilmiy jurnali. – 2022. – С. 303-306
  78. 78. Рахимова Г. Ш. Креативный метод преподования “Учебная стопка” для студентов медицинских институтов и оценка эффективности его использования //BARQARORLIK VA YETAKCHI TADQIQOTLAR ONLAYN ILMIY JURNALI. – 2022. – С. 56-61.
  79. 79. Rakhimova G. S., Kadirova L. V. THE USE OF INTERACTIVE METHODS TO ASSESS THE LEVEL OF ASSIMILATION OF THE MATERIAL STUDIED IN PATHOLOGICAL PHYSIOLOGY //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – Т. 2. – №. 1. – С. 463-469.
  80. 80. Rakhimova G. S., Kadirova L. V. THE INTERACTIVE USAGE OF METHODS TO ASSESS THE LEVEL OF ASSIMILATION OF THE MATERIAL STUDIED IN PATHOLOGICAL PHYSIOLOGY //Oriental renaissance: Innovative, educational, natural and social sciences. – 2022. – Т. 2. – №. 1. – С. 513-518.
  81. 81. Sh R. G., Kadirova L. V. The condition of some endocrine glands of white rats after an experimental traumatic brain injury //The new day in medicine. – 2021. – №. 5. – С. 37.